Free Trial

Inhibrx Biosciences (INBX) Competitors

Inhibrx Biosciences logo
$16.28 +0.55 (+3.46%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INBX vs. AVXL, COGT, CMRX, CDMO, AVBP, SNDX, IMNM, QURE, PHAR, and XERS

Should you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Anavex Life Sciences (AVXL), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), ArriVent BioPharma (AVBP), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), uniQure (QURE), Pharming Group (PHAR), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

Inhibrx Biosciences vs. Its Competitors

Anavex Life Sciences (NASDAQ:AVXL) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

In the previous week, Anavex Life Sciences had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Anavex Life Sciences and 1 mentions for Inhibrx Biosciences. Anavex Life Sciences' average media sentiment score of 0.45 beat Inhibrx Biosciences' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anavex Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibrx Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Inhibrx Biosciences has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$43M-$0.55-19.49
Inhibrx Biosciences$200K1,179.03$1.69B$116.750.14

Anavex Life Sciences' return on equity of -40.93% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -40.93% -36.38%
Inhibrx Biosciences N/A -85.12%-58.90%

Anavex Life Sciences presently has a consensus price target of $44.00, suggesting a potential upside of 310.45%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Anavex Life Sciences is more favorable than Inhibrx Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Inhibrx Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Anavex Life Sciences has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500.

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Anavex Life Sciences beats Inhibrx Biosciences on 10 of the 15 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INBX vs. The Competition

MetricInhibrx BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$236.39M$2.92B$5.56B$9.05B
Dividend YieldN/A2.44%5.24%3.99%
P/E Ratio0.1421.5627.6520.23
Price / Sales1,179.03283.26419.56119.26
Price / Cash0.1441.7026.2128.59
Price / Book1.767.538.035.65
Net Income$1.69B-$55.14M$3.18B$249.15M
7 Day Performance12.86%4.61%2.93%3.28%
1 Month Performance16.99%0.90%1.72%3.95%
1 Year Performance26.34%5.40%34.39%20.98%

Inhibrx Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INBX
Inhibrx Biosciences
0.9895 of 5 stars
$16.29
+3.5%
N/A+26.3%$236.39M$200K0.14166
AVXL
Anavex Life Sciences
3.6022 of 5 stars
$9.22
-2.7%
$44.00
+377.2%
+155.8%$809.33MN/A-16.7640Positive News
COGT
Cogent Biosciences
2.5922 of 5 stars
$7.18
+1.1%
$14.43
+101.0%
-9.8%$808.38MN/A-3.9080News Coverage
Analyst Revision
CMRX
Chimerix
0.6197 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6863 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+68.4%$799.18M$139.91M-5.23320High Trading Volume
AVBP
ArriVent BioPharma
1.7389 of 5 stars
$21.77
-5.0%
$40.00
+83.7%
+11.6%$783.81MN/A-5.7740
SNDX
Syndax Pharmaceuticals
3.1224 of 5 stars
$9.36
+3.5%
$35.80
+282.5%
-55.7%$777.87M$23.68M-2.42110
IMNM
Immunome
2.4317 of 5 stars
$9.30
+6.0%
$23.33
+150.9%
-27.6%$763.10M$9.04M-2.9240High Trading Volume
QURE
uniQure
2.1206 of 5 stars
$13.94
+0.6%
$37.82
+171.3%
+277.2%$759.19M$27.12M-3.18500News Coverage
PHAR
Pharming Group
2.8881 of 5 stars
$10.68
-2.9%
$30.00
+181.0%
+27.2%$748.58M$297.20M-53.38280Positive News
Gap Down
High Trading Volume
XERS
Xeris Biopharma
3.6202 of 5 stars
$4.67
-0.6%
$6.25
+33.8%
+125.4%$735.01M$222.55M-15.57290

Related Companies and Tools


This page (NASDAQ:INBX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners